News About: Pharm. Affairs
‘Velcade’ generic market of KRW 20 billion will open next year
Boryung Pharm will enter competition of Velcade(bortezomib, Janssen Korea) generics, a blockbuster multiple myeloma treatment.
According to the Ministry of Food and Drug Safety and the industry concerned on the 17th,...
Peerless Aronamin and Gelfos, “Revived OTC market”
Effort of domestic pharmaceutical companies, which turned their focus towards the OTC drug industry due to the shrunken ETC drug business environment, has been slowly highlighted.
Growth of products, which stressed t...
Health insurance benefit, another obstacle for Xeljanz to overcome
‘Xeljanz(generic name: tofacitinib),’ the world’s first oral rheumatoid arthritis treatment, has gotten over the wall of leading large hospitals in Korea.
However, due to the limitation in the health insurance benefi...
Reverse argument by MSD Korea, “No way! Gardasil is much cost-effective”
Although same data was used to analyze cost effectiveness, a result was completely reversed.
On the 16th, MSD Korea announced an analysis result of comparing cases of vaccinating Gardasil, a cervical cancer vaccine, ...
KPIC’s program to collect patient information, ‘PM2000,’ is finally kicked out
‘PM2000,’ a program for pharmacies to claim dispensation of prescriptions, which became a route for the Korea Pharmaceutical Information Center(KPIC) to illegally collect patient information, will finally be eradicate...
The largest therapeutic category was ‘Antipyretics & Analgesics’
It was observed antipyretic & analgesic drugs accounts for the highest portion of the total approved pharmaceutical products in Korea.
According to the therapeutic categories of 2014, approved by the Ministry of Food...
‘Aripiprazole’ schizophrenia market opens by its PMS expiration
The market of ‘aripiprazole’ drugs, schizophrenia treatments whose patent will be expired in PMS, will widely open on the coming 20th.
According to the Ministry of Food and Drug Safety, the number of products which a...
Weakened growth rates of leading PPI inhibitors; domestic ones making advances
Although the growth rates of leading proton pump inhibitors(PPI) have been weakened, their domestic drugs seem to make an advance.
According to the UBIST data of the third quarter of 2015 on the 11th, 9 of the top 15...
PMS expiration of Twynsta on August next year
‘Twynsta(telmisasrtan-amlodipine),’ the top sales hypertension treatment, has active competition ahead for the same substance drug due to expiration of post-marketing surveillance(PMS) on August next year.
A number o...
Syrup and contrast medium are about to be eradicated from the market
The pharmaceutical industry has raised a voice of concern regarding pharmaceutical products such as syrup and contrast medium, which will be excluded from the object of protection by the provision organization of low-...
